---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-25-000058"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:22:57.770929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcutis appoints Latha Vairavan as CFO; David Topper to retire effective May 15, 2025

## Summary
- Latha Vairavan appointed SVP and CFO effective prior to Q1 10-Q filing; David Topper to retire with transition support through May 15, 2025.
- Vairavan's base salary increased to $450,000, target annual bonus 45% of salary (max 67.5%), pro-rated for 2025.
- Vairavan granted option to purchase 60,000 shares and 20,000 restricted stock units with standard vesting.
- Topper's retirement not due to any dispute; he will receive severance benefits per existing agreement subject to release.

## SEC filing metadata
- accession: 0001787306-25-000058
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000058/0001787306-25-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000058/arqt-20250410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-25-000058
- JSON: https://secwatch.observer/filing/0001787306-25-000058.json
- Plain text: https://secwatch.observer/filing/0001787306-25-000058.txt

## Key facts
- Executive change
  David Topper departed as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
  - Action: retire
  - Role: Chief Financial Officer
  source text: Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000058/0001787306-25-000058-index.htm
- Executive change
  Latha Vairavan was appointed as Senior Vice President and Chief Financial Officer at Arcutis Biotherapeutics, Inc..
  - Action: appointed
  - Role: Senior Vice President and Chief Financial Officer
  source text: On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730625000058/0001787306-25-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.